Articles: covid-19.
-
Observational Study
Assessing the impact of comorbidities on disease severity in COVID-19 patients requires consideration of age.
Older age and comorbidities are risk factors for increased coronavirus disease 2019 (COVID-19) severity, but few studies have explored their interaction. This study aimed to assess the actual impacts of these factors on disease severity in COVID-19. The enrolled COVID-19 patients were divided into 4 age subgroups (≤44, 45-59, 60-74, and ≥75 years). ⋯ When comorbidities alone were used to predict disease severity, only the predictions were consistent with real outcomes in patients aged ≥75 years, compared with the predictions of high-risk comorbidities mentioned in World Health Organization and Chinese guidelines (Kappa 0.106, P < .05). Although older age and comorbidities were risk factors for severe COVID-19, their effects on disease severity varied across age groups. Additionally, comorbidities had a greater impact on COVID-19 severity in younger patients.
-
Anesthesia and analgesia · Jan 2025
The Association of the Coronavirus Disease-2019 Pandemic With Disparities in Maternal Outcomes.
In the United States, Black and Hispanic patients have substantially worse maternal outcomes than non-Hispanic White patients. The goals of this study were to evaluate the association between the coronavirus disease-2019 (COVID-19) pandemic and maternal outcomes, and whether Black and Hispanic patients were disproportionately affected by the pandemic compared to White patients. ⋯ In this national study of 2.5 million deliveries in the United States, the COVID-19 pandemic was associated with increases in maternal mortality and failure-to-rescue but not in severe maternal morbidity or cesarean deliveries. While the pandemic did not exacerbate disparities for Black and Hispanic patients with private or Medicaid insurance, uninsured Black patients experienced greater increases in mortality and failure-to-rescue compared to insured White patients.
-
This paper provides an overview of the efficacy of vitamin C for preventing and treating respiratory infections. Studies in a wide variety of animals have shown vitamin C to be protective against infections. In controlled trials in the general human population, vitamin C at a dose greater than 1 g/day did not prevent common colds. ⋯ It is unlikely that vitamin C would reduce the risk of pneumonia in the general population; however, 4 trials reported a treatment benefit for pneumonia patients, although the findings encourage further research rather than providing firm evidence of efficacy. Vitamin C has been tested for efficacy in COVID‑19 and sepsis with conflicting results. Given the evidence that vitamin C reduces the severity and duration of the common cold, paired with its good safety profile and low cost, it is not unreasonable for patients to test whether therapeutic vitamin C supplementation at a dose of 6-8 g/day is beneficial at the individual level.
-
Many studies have found more severe COVID-19 outcomes in migrants and ethnic minorities throughout the COVID-19 pandemic, while recent evidence also suggests higher risk of longer-term consequences. We studied the risk of a long COVID diagnosis among adult residents in Sweden, dependent on country of birth and accounting for known risk factors for long COVID. ⋯ The greater exposure and impact of the COVID-19 virus among migrants also affected longer-term consequences. Disease severity was the most important risk factor for long COVID in migrants. The findings emphasize the need for targeted health interventions for migrant communities during an infectious disease pandemic, such as strategic vaccination campaigns and extending social insurance schemes, focusing on reducing disease severity to mitigate the longer-term health consequences of an infection.